Amneal Form 4: Director John Kiely Sells 32,000 Shares at ~$9.23

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Amneal Pharmaceuticals director John Kiely reported a sale of Class A common stock on 08/27/2025. The Form 4 shows 32,000 shares were sold at a weighted-average price of $9.23 per share (prices ranged $9.20–$9.25). After the sale, the reporting person beneficially owned 225,433 shares, held directly. The filing was signed by an attorney-in-fact on 08/28/2025. The Form 4 discloses the transaction details and the footnote states the seller will provide a breakdown of shares sold at each price upon request.

Positive

None.

Negative

Director sale of 32,000 shares reduces the reporting person's direct holding and may be viewed as insider selling activity
Post-transaction ownership reduced to 225,433 shares, reflecting a material change in individual holdings disclosed on Form 4

Insights

TL;DR: Director John Kiely sold 32,000 shares, reducing his direct stake to 225,433 shares; disclosure appears complete.

The Form 4 indicates a routine insider disposition rather than a new issuance or transfer to related parties. The filing includes a weighted-average sale price and a footnote offering to provide price-by-price detail, which aligns with disclosure expectations. The sale was processed through an attorney-in-fact, as evidenced by the signature, which is common practice when the insider delegates execution. No amendment or additional arrangements are disclosed in this filing.

TL;DR: Insider sale of 32,000 shares at ~$9.23 lowers ownership but provides no new operational or financial information.

The transaction is a disposal of existing Class A common stock; the weighted-average price of $9.23 and the post-transaction holding of 225,433 shares are the material data points. This Form 4 does not include any derivative transactions or commentary on company performance, so it is a disclosure of insider liquidity rather than a signal about corporate fundamentals based solely on the filing content.

Insider Trade Summary

Net Seller: 32,000 shares ($295,360)

Net Sell 1 txn

Insider Kiely John

Role Director

Sold 32,000 shs ($295K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	32,000	$9.23	$295K

Holdings After Transaction: Class A Common Stock — 225,433 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

08/28/2025 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiely John

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	08/27/2025		S		32,000	D	$9.23⁽¹⁾	225,433	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Amneal (AMRX) director John Kiely disclose on Form 4?

John Kiely disclosed a sale of 32,000 Class A common shares on 08/27/2025 at a weighted-average price of $9.23 per share.

How many Amneal shares does the reporting person own after the reported sale?

The reporting person beneficially owned 225,433 shares following the transaction.

At what price range were the 32,000 shares sold?

Shares were sold at prices ranging from $9.20 to $9.25 per share; the Form 4 reports a weighted-average price of $9.23.

When was the Form 4 signed and by whom?

The Form 4 was signed by Denis Butkovic, Attorney-in-Fact, on 08/28/2025.

Does the filing show any derivative transactions or acquisitions?

No. The Form 4 only reports a non-derivative disposition of Class A common stock; no derivative transactions or acquisitions are disclosed.